<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04640532</url>
  </required_header>
  <id_info>
    <org_study_id>KRT-232-113</org_study_id>
    <nct_id>NCT04640532</nct_id>
  </id_info>
  <brief_title>KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kartos Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Telios Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kartos Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or&#xD;
      Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant&#xD;
      Myelofibrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cohorts 1 and 2 will undergo dose finding and dose expansion. Eligible patients will be&#xD;
      randomly assigned to an open cohort, either Cohort 1 or Cohort 2. Cohort 3 will be conducted&#xD;
      as a dose expansion, independent of Cohorts 1 and 2.&#xD;
&#xD;
      Cohort 1 will follow a 3+3 dose escalation design to determine the maximum tolerated dose&#xD;
      (MTD)/maximum administered dose (MAD) and recommended Phase 2 dose (RP2D) of TL-895&#xD;
      administered QD in combination with KRT-232. A Safety Review Committee (SRC) will review the&#xD;
      safety data during the dose escalation to decide on dose escalation and/or exploration of&#xD;
      intermediate doses.&#xD;
&#xD;
      Cohort 2 will follow a 3+3 dose escalation design to determine the MTD/MAD and recommended&#xD;
      RP2D of TL-895 administered BID in combination with KRT-232. An SRC will review the safety&#xD;
      data during the dose escalation to decide on dose escalation and/or exploration of&#xD;
      intermediate doses.&#xD;
&#xD;
      Cohort 3 will be conducted a 2-stage design. In stage 1, enrollment will continue until 15&#xD;
      evaluable patients have been enrolled. An SRC will review the data during the study and if&#xD;
      there are ≥4 responders based on the futility criteria and safety data from Stage 1, Cohort 3&#xD;
      expansion will commence. If there are ≤3 patients responding to therapy, Cohort 3 will be&#xD;
      terminated. Once expansion criteria have been met, Cohort 3 will be expanded to a total of 46&#xD;
      evaluable patients for Stage 2 analyses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2020</start_date>
  <completion_date type="Anticipated">July 24, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 11, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b - The MTD/MAD and RP2D of TL-895 in combination with KRT-232 in patients with R/R MF (Cohort 1 and Cohort 2)</measure>
    <time_frame>56 Days</time_frame>
    <description>DLTs will be used to establish the MTD. RP2D will be determined by the SRC based on safety data from the combination of TL-895 and KRT-232.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 - Spleen response rate for each cohort</measure>
    <time_frame>24 Weeks</time_frame>
    <description>A reduction in spleen volume as assessed by MRI (or CT) ≥ 35% from baseline at Week 24</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Symptom Score (TSS)</measure>
    <time_frame>24 Weeks</time_frame>
    <description>The change in TSS based Myelofibrosis Symptom Assessment Form version 4.0 (MFSAF v4.0)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Myelofibrosis</condition>
  <condition>Post-PV MF</condition>
  <condition>Post-ET Myelofibrosis</condition>
  <condition>Primary Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1 (R/R MF), Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TL-895 at 200 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle.&#xD;
KRT-232 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 (R/R MF), Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TL-895 at 300 mg once a day (QD) continuously starting on Cycle 1 Day 1 in a 28-day cycle.&#xD;
KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (R/R MF), Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TL-895 at 100 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle.&#xD;
KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 (R/R MF), Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TL-895 at 150 mg twice a day (BID) continuously starting on Cycle 1 Day 1 in a 28-day cycle.&#xD;
KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle starting on Cycle 2 Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 (JAKi Intolerant MF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRT-232 at 240mg will be administered orally, once daily (QD), on days 1-7 in a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KRT-232</intervention_name>
    <description>KRT-232, administered by mouth</description>
    <arm_group_label>Cohort 1 (R/R MF), Dose Level 1</arm_group_label>
    <arm_group_label>Cohort 1 (R/R MF), Dose Level 2</arm_group_label>
    <arm_group_label>Cohort 2 (R/R MF), Dose Level 1</arm_group_label>
    <arm_group_label>Cohort 2 (R/R MF), Dose Level 2</arm_group_label>
    <arm_group_label>Cohort 3 (JAKi Intolerant MF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TL-895</intervention_name>
    <description>TL-895, administered by mouth</description>
    <arm_group_label>Cohort 1 (R/R MF), Dose Level 1</arm_group_label>
    <arm_group_label>Cohort 1 (R/R MF), Dose Level 2</arm_group_label>
    <arm_group_label>Cohort 2 (R/R MF), Dose Level 1</arm_group_label>
    <arm_group_label>Cohort 2 (R/R MF), Dose Level 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of primary MF, post-PV MF, or post-ET MF, (WHO 2016)&#xD;
&#xD;
          -  ECOG ≤ 2&#xD;
&#xD;
          -  Cohort 1 and Cohort 2: R/R following JAK inhibitor treatment&#xD;
&#xD;
          -  Cohort 3: patients who are intolerant to JAK inhibitor treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with MDM2 inhibitors or p53-directed therapies&#xD;
&#xD;
          -  Prior treatment with a BCR-ABL, phosphoinositide 3-kinase (PI3k), mammalian target of&#xD;
             rapamycin (mTOR), bromodomain and extraterminal domain (BET), histone deacetylase&#xD;
             (HDAC), or spleen tyrosine kinase (Syk) inhibitor&#xD;
&#xD;
          -  Prior splenectomy&#xD;
&#xD;
          -  Splenic irradiation within 3 months prior to the first dose of study treatment&#xD;
&#xD;
          -  Clinically significant thrombosis within 3 months of screening&#xD;
&#xD;
          -  Grade 2 or higher QTc prolongation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>John Mei</last_name>
    <phone>650-542-0136</phone>
    <email>jmei@kartosthera.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irene Dea</last_name>
    <phone>(650) 839-7341</phone>
    <email>idea@kartosthera.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Oncology Institute of Hope</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <zip>90603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lake City Cancer Center</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (MSKCC)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski, Pleven</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Dr. Georgi Plovdiv</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nice Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samdzielny Publiczny Zaklad</name>
      <address>
        <city>Katowice</city>
        <zip>40-519</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nasz Lekarz Medical Outpatient Clinics Slawomir Jeka</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>France</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2020</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed/Refractory Myelofibrosis</keyword>
  <keyword>Janus associated Kinase Inhibitor-Intolerant Myelofibrosis</keyword>
  <keyword>MDM2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

